Nag, N and Millar, J and Davis, ID and Costello, S and Duthie, JB and Mark, S and Delprado, W and Smith, D and Pryor, D and Galvin, D and Sullivan, F and Murphy, AC and Roder, D and Elsaleh, H and Currow, D and White, C and Skala, M and Moretti, KL and Walker, T and De Ieso, P and Brooks, A and Heathcote, P and Frydenberg, M and Thavaseelan, J and Evans, SM, Development of indicators to assess quality of care for prostate cancer, European Urology Focus, 4, (1) pp. 57-63. ISSN 2405-4569 (2018) [Refereed Article]
Copyright 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Background: The development, monitoring, and reporting of indicator measures that describe standard of care provide the gold standard for assessing quality of care and patient outcomes. Although indicator measures have been reported, little evidence of their use in measuring and benchmarking performance is available. A standard set, defining numerator, denominator, and risk adjustments, will enable global benchmarking of quality of care.
Objective: To develop a set of indicators to enable assessment and reporting of quality of care for men with localised prostate cancer (PCa).
Design, setting, and participants: Candidate indicators were identified from the literature. An international panel was invited to participate in a modified Delphi process. Teleconferences were held before and after each voting round to provide instruction and to review results.
Outcome measurements and statistical analysis: Panellists were asked to rate each proposed indicator on a Likert scale of 1–9 in a two-round iterative process. Calculations required to report on the endorsed indicators were evaluated and modified to reflect the data capture of the Prostate Cancer Outcomes Registry–Australia and New Zealand (PCOR-ANZ).
Results and limitations: A total of 97 candidate indicators were identified, of which 12 were endorsed. The set includes indicators covering pre-, intra-, and post-treatment of PCa care, within the limits of the data captured by PCOR-ANZ.
Conclusions: The 12 endorsed quality measures enable international benchmarking on the quality of care of men with localised PCa. Reporting on these indicators enhances safety and efficacy of treatment, reduces variation in care, and can improve patient outcomes.
Patient summary: PCa has the highest incidence of all cancers in men. Early diagnosis and relatively high survival rates mean issues of quality of care and best possible health outcomes for patients are important. This paper identifies 12 important measurable quality indicators in PCa care.
|Item Type:||Refereed Article|
|Keywords:||prostate cancer, quality indicators, quality measures, clinical registries, population health|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Oncology and carcinogenesis|
|Research Field:||Cancer therapy (excl. chemotherapy and radiation therapy)|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||White, C (Dr Craig White)|
|Web of Science® Times Cited:||13|
Repository Staff Only: item control page